Trial
NCT03739606
Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer
Phase IIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
City of Hope Medical Center
Collaborators
National Cancer Institute (NCI)
Condition
Acute Biphenotypic Leukemia
Intervention
Anti-CD123/CD3 Monoclonal Antibody MGD006
Why stopped
RSS recommendation
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-12-17